These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1340 related articles for article (PubMed ID: 23255137)

  • 1. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
    Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
    Chung SS; Giehl N; Wu Y; Vadgama JV
    Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
    Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
    Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.
    Korkaya H; Kim GI; Davis A; Malik F; Henry NL; Ithimakin S; Quraishi AA; Tawakkol N; D'Angelo R; Paulson AK; Chung S; Luther T; Paholak HJ; Liu S; Hassan KA; Zen Q; Clouthier SG; Wicha MS
    Mol Cell; 2012 Aug; 47(4):570-84. PubMed ID: 22819326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
    Ithimakin S; Day KC; Malik F; Zen Q; Dawsey SJ; Bersano-Begey TF; Quraishi AA; Ignatoski KW; Daignault S; Davis A; Hall CL; Palanisamy N; Heath AN; Tawakkol N; Luther TK; Clouthier SG; Chadwick WA; Day ML; Kleer CG; Thomas DG; Hayes DF; Korkaya H; Wicha MS
    Cancer Res; 2013 Mar; 73(5):1635-46. PubMed ID: 23442322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
    Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 and breast cancer stem cells: more than meets the eye.
    Korkaya H; Wicha MS
    Cancer Res; 2013 Jun; 73(12):3489-93. PubMed ID: 23740771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
    Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
    J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.
    Ding K; Banerjee A; Tan S; Zhao J; Zhuang Q; Li R; Qian P; Liu S; Wu ZS; Lobie PE; Zhu T
    J Biol Chem; 2014 Jun; 289(23):16057-71. PubMed ID: 24737320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.
    Voutsadakis IA
    Clin Transl Oncol; 2019 May; 21(5):539-555. PubMed ID: 30306401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
    Lesniak D; Sabri S; Xu Y; Graham K; Bhatnagar P; Suresh M; Abdulkarim B
    PLoS One; 2013; 8(8):e71987. PubMed ID: 23991019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.